Abstract:Abstract Background As the most prevalent acquired bleeding disorder in adults, primary immune thrombocytopenia (ITP) and its underlying immune aberrations have been intensely investigated. Beyond the previously described Th1/Th2 imbalance, the role of Th17/Treg dysregulation has become the focus of attention. It was reported by our group that Tregs from untreated ITP patients demonstrated decreased IL-10 secretion and compromised control upon over-activated T effector cells (Li et al. 2015). The mechanism of Treg dysregulation under autoimmunity conditions is yet to be revealed. It has been recently argued by several research groups that the functional plasticity of Treg cell linage is dynamically regulated under inflammation via instability of Foxp3 expression, which means that Tregs can lose Foxp3 expression to gain effector T cell function in inflammatory milieu. The present study evaluated phenotypic features and gene expression traits of purified CD4+ T helper cells from ITP patients before and after glycocorticoids treatment, thus intending to investigate Treg functional plasticity among ITP patients. Methods CD4+ T helper cells were obtained via magnetic activated cell sorting from peripheral blood of 8 primary ITP patients before and after glycocorticoids treatment and 4 healthy volunteers. The phenotypic features were determined by FACS Canto II system with surface staining of CD25 and CD127, as well as cytoplasmic staining of IFN-γ and IL-17. Gene expression profiling was performed via QIAGEN Human T Helper Cell Differentiation PCR Array. Results The pre-treatment platelet count was (7±7)*109/L among 8 ITP patients (2 males and 6 females, median age 57.0 years), and the post-treatment platelet count was restored to (158±63)*109/L after high-dose dexamethasone regimen (40mg/d*4d). Gene expression profiling revealed that Foxp3 (-2.8 folds, p=0.001), TNF (-4.0 folds, p=0.003), and Stat1 (-2.3 folds, p=0.001) levels were significantly down-regulated among untreated ITP patients, while IL-17A (3.6 folds, p=0.05) was up-regulated with marginal statistical significance. The percentage of CD25+ CD127- population in CD4+ cells was similar among 3 groups (pre-treatment ITP: 3.1±0.6%, post-treatment ITP: 3.2±0.7%, health control: 3.4±0.8%). Among CD4+ CD25+ CD127- population, the percentage of IL-17+ cells was elevated in pre-treatment ITP patients (2.9±1.8% vs. 1.4±0.2%, p=0.17), and significantly decreased after high-dose dexamethasone regimen (1.5±1.1% vs. 2.9±1.8%, p=0.035), while the percentage of IFN-γ+ cells was similar among 3 groups (pre-treatment ITP: 18.5±12.6%, post-treatment ITP: 11.1±9.5%, health control: 18.5±3.8%). Conclusions Among primary ITP patients, Foxp3 expression was significantly decreased in their CD4+ T helper cells, which was inconsistent with the almost stable CD4+ CD25+ CD127- percentages determined by flow cytometry between ITP patients and healthy volunteers. Within the Treg population, we demonstrated elevated IL-17 expressing cells in pre-treatment ITP patients, which could be restored after high-dose dexamethasone regimen. These findings favored the argument of the functional plasticity of Treg cell linage during autoimmunity, and corresponded to Th17 dysregulation previously described in primary ITP. Disclosures No relevant conflicts of interest to declare.

Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura

Effects of High-Dose Dexamethasone on Regulating Interleukin-22 Production and Correcting Th1 and Th22 Polarization in Immune Thrombocytopenia

Correction of Th1-dominant Cytokine Profiles by High-dose Dexamethasone in Patients with Chronic Idiopathic Thrombocytopenic Purpura

Changes in Follicular Helper T Cells in Idiopathic Thrombocytopenic Purpura Patients.

Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia.

Circulating Dendritic Cells Subsets and CD4+Foxp3+ Regulatory T Cells in Adult Patients with Chronic ITP Before and after Treatment with High‐dose Dexamethasome

The Abnormal Function of CD39+ Regulatory T Cells Could Be Corrected by High-Dose Dexamethasone in Patients with Primary Immune Thrombocytopenia

Dexamethasone Suppresses the Th17/1 Cell Polarization in the CD4+ T Cells from Patients with Primary Immune Thrombocytopenia.

Influences of High-Dose Dexamethasone on Regulatory T Cells, Transforming Growth Factor-β1 and Interleukin-10 of Patients with Chronic ITP.

Pulsed High-dose Dexamethasone Improves Interleukin 10 Secretion by CD5 + B Cells in Patients with Primary Immune Thrombocytopenia

High-Dose Dexamethasone Corrects the Elevated Level of IL-16 in Immune Thrombocytopenia

Classificatory Treatment of Refractory Idiopathic Thrombocytopenic Purpura

High-dose Dexamethasone Modulates Serum Cytokine Profile in Patients with Primary Immune Thrombocytopenia.

Effect of high dose dexamethasone on function and TLR-9 mRNA expression of plasmacytoid dendritic cells in patients with immune thrombocytopenic purpura]

[Curative Efficacy of Rituximab for ITP Patients with Different Sensitivity to Hormone].

High-dose Dexamethasone Corrects Impaired Myeloid-Derived Suppressor Cell Function Via Ets1 in Immune Thrombocytopenia.

The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

[Conventional Dose of Prednisone Regulates Th-associated Gene Expression in De Novo ITP Patients].

Functional Plasticity in CD4+ CD25+ CD127- Treg Population in Primary Immune Thrombocytopenia

[Effect of High-Dose Dexamethasone on BAFF and Tregs in Patients with Immune Thrombocytopenic Purpura.].